Kantonsspital St.Gallen

Finch 302 Gilead

Carina Hutz & Mira Bartz Batliner

abstract A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase
3 Study to Assess the Efficacy and Safety of Filgotinib Administered
for 24 weeks in Combination with Conventional Synthetic
Disease-modifying Anti-rheumatic Drug(s) (csDMARDs) to Subjects
with Moderately to Severely Active Rheumatoid Arthritis Who Have
an Inadequate Response to Biologic DMARD(s) Treatment
type of project clinical studies
status completed
start of project 2017
end of project 2018
responsible person Dr. med. Rüdiger Müller